622867-52-1 Usage
Description
Tert-butyl 6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate is a complex organic compound with a molecular structure that features a 3,4-dihydroisoquinoline core, a hydroxymethyl group at the 6th position, and a carboxylate group at the 2nd position, with a tert-butyl group attached. tert-butyl 6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate is characterized by its potential reactivity and structural diversity, making it a versatile building block in organic synthesis and pharmaceutical chemistry.
Uses
Used in Pharmaceutical Industry:
Tert-butyl 6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate is used as an intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific therapeutic properties.
Used in HIV Treatment:
In the pharmaceutical industry, tert-butyl 6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate is used as a key intermediate in the preparation of phosphonate-substituted HIV protease inhibitors. These inhibitors play a crucial role in the treatment of AIDS and other viral infections by disrupting the replication process of the virus.
Used in Immunosuppressant Synthesis:
tert-butyl 6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate is also utilized in the synthesis of immunosuppressant heterocyclic compounds. These immunosuppressants are essential in treating or preventing diseases associated with EDG receptor-mediated signal transduction, which can lead to various autoimmune and inflammatory conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 622867-52-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,2,2,8,6 and 7 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 622867-52:
(8*6)+(7*2)+(6*2)+(5*8)+(4*6)+(3*7)+(2*5)+(1*2)=171
171 % 10 = 1
So 622867-52-1 is a valid CAS Registry Number.
622867-52-1Relevant articles and documents
PLASMA KALLIKREIN INHIBITORS
-
Page/Page column 104; 133, (2021/02/19)
The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof
-
Paragraph 0210; 0213, (2017/10/10)
Benzenesulfonyl-asymmetric ureas are provided for the treatment of conditions modulated by the ghrelin receptor.
SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1
-
Page/Page column 643-644, (2018/01/20)
The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.